Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the
FactSet Research Systems Inc. (NYSE: FDS) is expected to report its financial results for the fourth quarter fiscal 2023, ending Aug. 31, 2023, before the opening bell on Sept. 21, 2023.
The native token of the non-fungible tokens (NFT) platform ImmutableX, known as IMX (CRYPTO: IMX), experienced a significant surge on Thursday, led by South Korean traders.